The Global Health Innovative Technology Fund (GHIT Fund) welcomed ten new partnerships that include major global pharmaceutical and biotechnology companies—collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.

“We are excited to welcome these new funding partners—from within Japan and across the globe—who have joined forces with the GHIT Fund because of their own unique commitments to global health, as well as their confidence that working together will transform R&D,” GHIT Fund CEO Dr. BT Slingsby said. “The partnerships will not only broaden our scope, but also increase our ability to reach the world’s most vulnerable people with lifesaving technology.”